496 related articles for article (PubMed ID: 31533850)
1. A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications.
Baxi SM; Beall R; Yang J; Mackey TK
Global Health; 2019 Sep; 15(1):57. PubMed ID: 31533850
[TBL] [Abstract][Full Text] [Related]
2. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey.
Fundytus A; Sengar M; Lombe D; Hopman W; Jalink M; Gyawali B; Trapani D; Roitberg F; De Vries EGE; Moja L; Ilbawi A; Sullivan R; Booth CM
Lancet Oncol; 2021 Oct; 22(10):1367-1377. PubMed ID: 34560006
[TBL] [Abstract][Full Text] [Related]
3. Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts.
Gleeson D; Lexchin J; Labonté R; Townsend B; Gagnon MA; Kohler J; Forman L; Shadlen KC
Global Health; 2019 Nov; 15(Suppl 1):78. PubMed ID: 31775767
[TBL] [Abstract][Full Text] [Related]
4. Essential cancer medicines in the national lists of countries of the WHO South-East Asia Region: a descriptive assessment.
Chivukula MV; Tisocki K
WHO South East Asia J Public Health; 2018 Sep; 7(2):90-98. PubMed ID: 30136667
[TBL] [Abstract][Full Text] [Related]
5. [Essential medicines and the TRIPS Agreement: collision between the right to health and intellectual property rights].
Allard Soto R
Salud Colect; 2015 Mar; 11(1):9-21. PubMed ID: 25853827
[TBL] [Abstract][Full Text] [Related]
6. What is the impact of intellectual property rules on access to medicines? A systematic review.
Tenni B; Moir HVJ; Townsend B; Kilic B; Farrell AM; Keegel T; Gleeson D
Global Health; 2022 Apr; 18(1):40. PubMed ID: 35428250
[TBL] [Abstract][Full Text] [Related]
7. 25 years of the WHO essential medicines lists: progress and challenges.
Laing R; Waning B; Gray A; Ford N; 't Hoen E
Lancet; 2003 May; 361(9370):1723-9. PubMed ID: 12767751
[TBL] [Abstract][Full Text] [Related]
8. Analysis of evidence supporting the Federation of Bosnia and Herzegovina reimbursement medicines lists: role of the WHO Essential Medicines List, Cochrane systematic reviews and technology assessment reports.
Mahmić-Kaknjo M; Marušić A
Eur J Clin Pharmacol; 2015 Jul; 71(7):825-33. PubMed ID: 25956715
[TBL] [Abstract][Full Text] [Related]
9. Impacts of intellectual property provisions in trade treaties on access to medicine in low and middle income countries: a systematic review.
Islam MD; Kaplan WA; Trachtenberg D; Thrasher R; Gallagher KP; Wirtz VJ
Global Health; 2019 Dec; 15(1):88. PubMed ID: 31888688
[TBL] [Abstract][Full Text] [Related]
10. Approaches to improving access to essential cancer medicines in the WHO South-East Asia Region.
Chivukula MV; Tisocki K
WHO South East Asia J Public Health; 2018 Sep; 7(2):62-66. PubMed ID: 30136662
[TBL] [Abstract][Full Text] [Related]
11. Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability.
Husain MJ; Datta BK; Kostova D; Joseph KT; Asma S; Richter P; Jaffe MG; Kishore SP
J Am Heart Assoc; 2020 May; 9(9):e015302. PubMed ID: 32338557
[TBL] [Abstract][Full Text] [Related]
12. Availability, Price and Affordability of Anticancer Medicines: Evidence from Two Cross-Sectional Surveys in the Jiangsu Province, China.
Zhu Y; Wang Y; Sun X; Li X
Int J Environ Res Public Health; 2019 Oct; 16(19):. PubMed ID: 31623326
[TBL] [Abstract][Full Text] [Related]
13. Access to generic antiretrovirals: inequality, intellectual property law, and international trade agreements.
Castro A; Westerhaus M
Cad Saude Publica; 2007; 23 Suppl 1():S85-96. PubMed ID: 17308722
[TBL] [Abstract][Full Text] [Related]
14. Public health-oriented intellectual property and trade policies in Africa and the regional mechanism under Trade-Related Aspects of Intellectual Property Rights amendment.
Adekola TA
Public Health; 2019 Aug; 173():1-4. PubMed ID: 31203136
[TBL] [Abstract][Full Text] [Related]
15. [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].
Chaves GC; Oliveira MA; Hasenclever L; de Melo LM
Cad Saude Publica; 2007 Feb; 23(2):257-67. PubMed ID: 17221075
[TBL] [Abstract][Full Text] [Related]
16. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
[TBL] [Abstract][Full Text] [Related]
17. The ethics of intellectual property rights in an era of globalization.
Shah AK; Warsh J; Kesselheim AS
J Law Med Ethics; 2013; 41(4):841-51, Table of Contents. PubMed ID: 24446942
[TBL] [Abstract][Full Text] [Related]
18. Availability, prices, and affordability of selected essential cancer medicines in a middle-income country - the case of Mexico.
Moye-Holz D; Ewen M; Dreser A; Bautista-Arredondo S; Soria-Saucedo R; van Dijk JP; Reijneveld SA; Hogerzeil HV
BMC Health Serv Res; 2020 May; 20(1):424. PubMed ID: 32410676
[TBL] [Abstract][Full Text] [Related]
19. Essential medicines for emergency care in Africa.
Broccoli MC; Pigoga JL; Nyirenda M; Wallis L; Calvello Hynes EJ
Emerg Med J; 2018 Jul; 35(7):412-419. PubMed ID: 29627770
[TBL] [Abstract][Full Text] [Related]
20. Could international compulsory licensing reconcile tiered pricing of pharmaceuticals with the right to health?
Ooms G; Forman L; Williams OD; Hill PS
BMC Int Health Hum Rights; 2014 Dec; 14():37. PubMed ID: 25518744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
